CoChat

Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression

Open access

Published version of a preprint

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Abstract

PURPOSE: CD8(+) T lymphocytes can kill autologous melanoma cells, but their activity is impaired when poorly immunogenic tumor phenotypes evolve in the course of disease progression. Here, we analyzed three consecutive melanoma lesions obtained within one year of developing stage IV disease for their recognition by autologous T cells. EXPERIMENTAL DESIGN: One skin (Ma-Mel-48a) and two lymph node (Ma-Mel-48b, Ma-Mel-48c) metastases were analyzed for T-cell infiltration. Melanoma cell lines established from the respective lesions were characterized, determining the T-cell-stimulatory capacity, expression of surface molecules involved in T-cell activation, and specific genetic alterations affecting the tumor-T-cell interaction. RESULTS: Metastases Ma-Mel-48a and Ma-Mel-48b, in contrast with Ma-Mel-48c, were infiltrated by T cells. The T-cell-stimulatory capacity was found to be strong for Ma-Mel-48a, lower for Ma-Mel-48b, and completely abrogated for Ma-Mel-48c cells. The latter proved to be HLA class I-negative due to an inactivating mutation in one allele of the beta-2-microglobulin (B2M) gene and concomitant loss of the other allele by a deletion on chromosome 15q. The same deletion was already present in Ma-Mel-48a and Ma-Mel-48b cells, pointing to an early acquired genetic event predisposing to development of β2m deficiency. Notably, the same chronology of genetic alterations was also observed in a second β2m-deficient melanoma model. CONCLUSION: Our study reveals a progressive loss in melanoma immunogenicity during the course of metastatic disease. The genetic evolvement of T-cell resistance suggests screening tumors for genetic alterations affecting immunogenicity could be clinically relevant in terms of predicting patient responses to T-cell-based immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-0567

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 177

Metadata

Authors
Sucker, A., Zhao, F., Real, B., Heeke, C., Bielefeld, N., Maβen, S., Horn, S., Moll, I., Maltaner, R., Horn, P. A., Schilling, B., Sabbatino, F., Lennerz, V., Kloor, M., Ferrone, S., Schadendorf, D., Falk, C. S., Griewank, K., & Paschen, A.
Affiliations
  • Essen University Hospital (DE)
  • Medizinische Hochschule Hannover (DE)
  • Massachusetts General Hospital (US)
  • Johannes Gutenberg University Mainz (DE)
  • Heidelberg University (DE)
Corresponding author
Paschen, Annette
Venue
Clinical Cancer Research
Published
2014-12-14
Volume
20
Issue
24
Pages
6593-6604
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2148590804
Cited by
171
References
50
Citations by year
2026: 7 · 2025: 5 · 2024: 8 · 2023: 20 · 2022: 18 · 2021: 26 · 2020: 19 · 2019: 22 · 2018: 20 · 2017: 15 · 2016: 8 · 2015: 3
FWCI
4.19
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
Funders
National Cancer Institute (R01CA110249, R01CA138188)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
melanoma, T cell resistance, CD8+ T cells, tumor immunogenicity, melanoma progression, metastasis, T cell infiltration, HLA class I deficiency, beta2-microglobulin, chromosome 15q deletion
MeSH terms
Alleles, beta 2-Microglobulin, Butorphanol, Humans, Melanoma, Mutation, Neoplasm Metastasis, Neoplasm Staging, Phenotype, Histocompatibility Antigens Class I, Gene Expression, Cluster Analysis, T-Lymphocyte Subsets, Cytokines, Lymphocytes, Tumor-Infiltrating, Disease Progression, Evolution, Molecular, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Cell Line, Tumor, B7 Antigens

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0567
The paper
Sucker, A., Zhao, F., Real, B., Heeke, C., Bielefeld, N., Maβen, S., Horn, S., Moll, I., Maltaner, R., Horn, P. A., Schilling, B., Sabbatino, F., Lennerz, V., Kloor, M., Ferrone, S., Schadendorf, D., Falk, C. S., Griewank, K., & Paschen, A. (2014). Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0567

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.